A modular constitutive single-plasmid platform for efficient production of a recombinant Strep A glycoconjugate vaccine
Abstract
Production of glycoconjugate vaccines has long relied upon chemical methods which are highly complex and expensive, resulting in vaccines that are not widely affordable. Heterologous bioconjugation methods, such as Protein-Glycan Coupling Technology (PGCT), have emerged as a path to significantly cheaper manufacture using safe host organisms, such as Escherichia coli , for recombinant glycoconjugate expression. PGCT glycoconjugate synthesis components are typically encoded across three plasmids and require the addition of exogenous chemical inducers for gene expression. In this study, we utilise modular DNA assembly to generate a single constitutive plasmid for biosynthesis of a Streptococcus pyogenes rhamnose polysaccharide glycoconjugate vaccine. This approach resulted in a greater than seven-fold glycoconjugate yield as well as simplified cell culture conditions compared to the traditional three plasmid inducible system. Importantly, given the modular nature of this method, this innovation could be applied to the manufacture of glycoconjugate vaccines against a range of pathogens.
Related
- Covalently Functionalized Two-Dimensional Red Phosphorus Nanosheets: Efficient Platform for Broad-Spectrum Biofilm Eradication
- Phase-Controlled Efficient Nitrate-to-Dinitrogen Electroreduction on an α-Co/NC@CNT Electrified Membrane Platform
- Concomitant Production and Transfer of Hydrogen for Efficient In Situ Reduction of C–C and C–O Unsaturated Substrates by Pt/TiO2 Photocatalyst in Ethanol
- Atomically Precise Platinum Nanocluster Catalysts for Efficient Hydrogen Production via Methylcyclohexane Dehydrogenation
- Ti@TiO2/Ni nanocomposite for efficient photothermal hydrogen production
BibTeX
@article{harrison2026modular,
title = {{A modular constitutive single-plasmid platform for efficient production of a recombinant Strep A glycoconjugate vaccine}},
author = {Mark A. Harrison and Tom L. Flood and Mark Reglinski and Mark McNeil and Helge C. Dorfmueller and Brendan W. Wren and Ian J. Passmore},
journal = {Communications Biology},
year = {2026},
month = oct,
doi = {10.1038/s42003-026-11158-z},
url = {https://www.nature.com/articles/s42003-026-11158-z},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A modular constitutive single-plasmid platform for efficient production of a recombinant Strep A glycoconjugate vaccine
AU - Mark A. Harrison
AU - Tom L. Flood
AU - Mark Reglinski
AU - Mark McNeil
AU - Helge C. Dorfmueller
AU - Brendan W. Wren
AU - Ian J. Passmore
PY - 2026
DA - 2026/10/10
JO - Communications Biology
DO - 10.1038/s42003-026-11158-z
UR - https://www.nature.com/articles/s42003-026-11158-z
AB - Production of glycoconjugate vaccines has long relied upon chemical methods which are highly complex and expensive, resulting in vaccines that are not widely affordable. Heterologous bioconjugation methods, such as Protein-Glycan Coupling Technology (PGCT), have emerged as a path to significantly cheaper manufacture using safe host organisms, such as Escherichia coli , for recombinant glycoconjugate expression. PGCT glycoconjugate synthesis components are typically encoded across three plasmids and require the addition of exogenous chemical inducers for gene expression. In this study, we utilise modular DNA assembly to generate a single constitutive plasmid for biosynthesis of a Streptococcus pyogenes rhamnose polysaccharide glycoconjugate vaccine. This approach resulted in a greater than seven-fold glycoconjugate yield as well as simplified cell culture conditions compared to the traditional three plasmid inducible system. Importantly, given the modular nature of this method, this innovation could be applied to the manufacture of glycoconjugate vaccines against a range of pathogens.
SN - 2399-3642
ER -